On July 13, 2026, the FDA approved Leqembi Iqlik (lecanemab-irmb), an amyloid-clearing antibody, as a shot that can start at home for early Alzheimer's. People with early Alzheimer's should read the headline as a new starting route, not a new drug and not freedom from brain-scan monitoring.
Eisai and BioArctic announced the decision in the FDA approval notice. It covers the same early-stage group already eligible for IV lecanemab. Home start changes where treatment begins, not whether doctors stay involved.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from Wcia — Use this primary source to verify the official announcement.
- Read the official notice from Drugtopics — Use this primary source to verify the official announcement.
Table of Contents
- Who qualifies for a home start?
- How do the doses compare?
- What does the evidence actually show?
- Which safety checks still need a clinic?
Who qualifies for a home start?
The at-home start is for adults with mild cognitive impairment or mild dementia due to Alzheimer's. Mild cognitive impairment means early memory or thinking changes that do not yet remove independence. Mild dementia means those changes have begun to affect daily tasks.
Drug Topics reports the same report limits use to people with confirmed amyloid pathology. Amyloid pathology means sticky amyloid plaques tied to Alzheimer's are present in the brain. A doctor must confirm that finding before treatment starts.
How do the doses compare?
The starting at-home regimen is 500 mg each week, given as two 250-mg shots. IV lecanemab is weight-based at 10 mg per kg every two weeks. Maintenance subcutaneous dosing is 360 mg each week, according to the Medscape dosing summary.
That same summary says the July 2026 action removed an older sequence. Patients no longer need 18 months of clinic IV treatment before switching to weekly 360-mg maintenance. The FDA had authorized that maintenance switch in August 2025.
What does the evidence actually show?
The shot did not have its own large outcomes trial. Approval rests on IV efficacy plus matching drug levels in blood and similar amyloid-plaque reduction. That matters because the direct proof of slower decline comes from IV treatment.
IV efficacy came mainly from CLARITY AD, described in the Drug Topics report. The trial enrolled 1,795 people with early Alzheimer's. Lecanemab beat placebo by 0.45 points on CDR-SB, a dementia rating scale, at 18 months while substantially lowering amyloid.
Which safety checks still need a clinic?
Home use does not end clinic oversight. Labeling calls for a baseline brain MRI, follow-up MRIs, close watch for amyloid-related imaging abnormalities during the first 14 weeks, and counseling about bleeding risk with anticoagulants.
Those abnormalities, called ARIA, are brain swelling or small bleeds seen on scans. A reader can use these practical checks before planning home shots: Do not start home shots until a professional has supervised at least two consecutive doses and judged home use appropriate.
- Ask whether baseline and follow-up MRIs are scheduled and who will review them quickly.
- Ask about ARIA warning signs during the first 14 weeks and where to call day or night.
- Review all blood thinners and bleeding risks with the prescribing team.
- Discuss APOE-e4 gene testing, since homozygotes face markedly higher ARIA risk, according to the Denkstrom summary of Eisai and FDA labeling.
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: How People With Early Alzheimer’s Can Read the FDA Headline Carefully
- Safety Questions After the 2026 LiBBY Dementia Trial: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- Midlife Monitoring Questions Raised by the AAIC 2026 Soccer Study: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
